Praxis (PRAX) news
Recent news
Praxis Precision Medicines, Inc.: Raymond James raises target price to $945 from $765
Praxis Precision Medicines (NASDAQ:PRAX) recently received a significant update from Raymond James Financial, which raised its price target for the stock to $945 from $765, maintaining a "Strong Buy" rating in its latest research report. This adjustment reflects the firm's continued confidence in…
AInvest Wire · Aug 17, 2026Perceptive Advisors exits drug, BLTE, EVMN, NMRA in 2Q: 13F
Perceptive Advisors LLC, a biotech-focused investment firm, disclosed its second-quarter 2026 portfolio changes in a recent 13F filing. The firm exited several positions, including drugmaker Belite Bio (BLTE), Evommune (EVMN), and Neumora Therapeutics (NMRA), as part of its strategic rebalancing…
AInvest Wire · Aug 14, 2026Praxis Precision Medicines, Inc. announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jul 2, 2026Praxis Precision Medicines - FDA extends review period for Relutrigine NDA for SCN2A and SCN8A DEES by three months
AInvest Wire · Jun 29, 2026Praxis Precision Medicines - FDA sets updated PDUFA date of December 27, 2026 for Relutrigine
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) recently announced that the U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2026, for its New Drug Application (NDA) for relutrigine, a first-in-class small molecule in…
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.